FAST NEWS: Connect Biopharma Plunges on Poor Results for Colitis Drug
The latest: Connect Biopharma (CNTB.US) said late on Tuesday that results from a Phase 2 trial for its CBP-307 drug for treatment of patients with moderate to severe ulcerative colitis…
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK -
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Pateo Connect revs up for IPO, belching widening losses and slumping margins
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
